Navigation Links
Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
Date:9/4/2008

MAIDENHEAD, England, September 4 /PRNewswire-FirstCall/ --

- Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide

Wyeth today announced that Cyprus and the Republic of Ireland have initiated national immunisation programmes (NIPs) for infants and young children against pneumococcal disease by adding Prevenar(TM) (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed), also called PCV7, to their national immunization schedules.(1) Including Ireland and Cyprus, this now makes 26 countries across the world that have included Prevenar in their NIPs.(1)

"Wyeth, the manufacturer of Prevenar, is pleased to be part of these initiatives and welcomes the introduction of this life-saving vaccine into national immunization schedules," says Dr E. David McIntosh, a paediatrician and European Medical Director, Infectious Diseases/Vaccines at Wyeth. "Wyeth is dedicated to the wellbeing of children and to continuing to work with governments and public health agencies to further expand access to Prevenar to help prevent serious and debilitating pneumococcal infections caused by serotypes contained in the vaccine. This includes facilitating the introduction of the vaccine in those countries that have announced their decision to include Prevenar in their national immunisation programmes but have yet to introduce the vaccine as part of their immunisation schedule."

Pneumococcal disease results in approximately 1.6 million deaths per year worldwide of which up to 1 million deaths are in children younger than five years of age.(2) Pneumococcal disease is the leading vaccine-preventable cause of death in children younger than five years of age worldwide.(3)

The World Health Organization (WHO) recommends priority inclusion of the 7-valent pneumococcal conjugate vaccine in national childhood immunization programs worldwide due to the significant burden of pneumococcal disease and demonstrated vaccine efficacy.(4) Recently, the Strategic Advisory Group of Experts (SAGE) to WHO issued a preliminary recommendation that pneumococcal disease prevention be ranked as a very high priority on a global basis.(5)

Prevenar(TM), the only licensed pneumococcal conjugate vaccine, is now available in 88 countries around the world, with more than 180 million doses distributed.(1)

Pneumococcal Disease

Pneumococcal disease affects both children and adults and is a leading cause of illness and death worldwide.(6) Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections, including otitis media.(7) Prevenar is the first and only pneumococcal conjugate vaccine approved to help protect infants and young children against pneumococcal disease caused by the serotypes included in the vaccine.(7)

Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

References:

1) Data on file, Wyeth Pharmaceuticals Inc.

2) March 2007-WHO position paper

3) Health Protection Agency (HPA): Centre for Infections.

Cumulative weekly number of reports of invasive pneumococcal disease

Due to any of the seven serotypes present in PCV-7: children <2 years

In England and Wales by epidemiological year: July-June (2003 to

date). Cumulative Weekly Report IPD. February 2008.

4) World Health Organization. Pneumococcal conjugate vaccine for

childhood immunization, March 2007- WHO position paper. Wkly Epidemiol

Record 2007;12:93-104.

5) World Health Organization. Meeting of the immunization Strategic

Advisory Group of Experts, November 2007 - conclusions and

recommendations. Wkly Epidemiol Record 2008; (83): 1-16.

6) Centers for Disease Control and Prevention. Prevention of

pneumococcal disease: recommendations of the Advisory Committee on

Immunization Practices (ACIP). MMWR. 1997;46(RR-8):1-24. Available at:

5236. Accessed February 14, 2008.

7) Summary of Product Characteristics for PREVENAR, Wyeth

Pharmaceuticals, Inc.


'/>"/>
SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite
2. Global Experts Explore Entire Spectrum of Aids Vaccine Development
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
5. Anthrax vaccine produces immunity with nanoparticles, not needles
6. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
7. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
8. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
9. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... business of innovation is taking over sports. On Thursday, December 15th a panel ... technology is disrupting the playing field at a Smart Talk session. Smart Talk ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today the ... KbioBox developed a sophisticated “3 click” gene dditing off target analysis program and ... website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
Breaking Biology Technology:
(Date:11/14/2016)...  xG Technology, Inc. ("xG" or the "Company") (Nasdaq: ... for use in challenging operating environments, announced its results ... will hold a conference call to discuss these results ... (details below). Key Recent Accomplishments ... agreement to acquire Vislink Communication Systems. The purchase is ...
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
Breaking Biology News(10 mins):